A lesson to be learned: the causes and the consequences of ivermectin use during the COVID-19 pandemic

(Credit: Unsplash)

This article was exclusively written for The European Sting by Ms. Ana Luiza Almeida Menezes and Ms. Emilly Mota Linhares, second year medical students in the Tiradentes University. They are affiliated with the International Federation of Medical Students Associations (IFMSA), cordial partner of The Sting. The opinions expressed in this piece belong strictly to the writers and do not necessarily reflect IFMSA’s view on the topic, nor The European Sting’s one.

The CoronaVirus pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has changed the way people live all over the world. Some symptoms include high temperature, continuous cough and loss or change to your sense of smell and taste. Besides that, it may cause fatigue, muscle pain and other debilitating damages to the heart, lungs and brain. According to Johns Hopkins University of Medicine, in late 2020, eighty-one percent of cases were categorized as mild, which symptomatic management at home and monitoring of clinical deterioration is recommended.

Due to lack of studies to determine the ideal type of treatment, many drugs were put into the spotlight as possible mitigators of coronavirus’ symptoms and long-term health effects. One of them is ivermectin, an inexpensive, already approved drug with a broad‐spectrum antiparasitic action, which has also been proven its antiviral potential in two RNA viruses, the West Nile virus, the Newcastle disease virus, and two DNA viruses, the pseudorabies virus and parvoviruses.

Ivermectin has become such a popular preventive drug in Latin American countries, like Peru, Bolivia and Guatemala, that scientists performing clinical trials struggled to recruit participants because so many were already taking it. Recent studies correlate the previously detected antiviral activity with its capability to act against the coronavirus, such as an in vitro study that presented the drug’s capacity of inhibition of SARS‐COV‐2 replication. Until october 2020, there were 40 clinical trials worldwide that  were testing the drug. 

The use of medical treatments must have a balance between risks and benefits as its main focus. The current evidences related to the effects of ivermectin in the combat against COVID-19 have low scientific quality due to the great risk of bias and the small amount of studies in humans.

In the recent researches using in vitro samples, it was noticed that ivermectin has shown effective action in combat against the multiplication of the virus. Moreover, the virus has as an effect the induction of an amplified immune response, causing a cytokine storm, responsible for the inflammation of lung tissue. Some studies indicate that ivermectin acts efficiently against the inflammatory downstream.

However, the findings suggest that ivermectin does not significantly affect the course of early COVID-19, some pharmacokinetic models showed that plasma total and unbound ivermectin levels do not reach the concentration that results in 50% of viral inhibition even for a dose level 10- 35 times higher than the approved doses.

In trials made with COVID-19 affected patients, there was a correlation between the use of ivermectin and a decreased number of deaths, especially in severe cases. Nevertheless, such studies showed multiple defects, specifically the small number of avaliated patients and not defined avaliation criteria,  making conclusive results impossible.

Lastly, it is important to emphasise that even though ivermectin has an antiviral action in the in vitro trials, its use in patients with COVID-19 is empirical and must be balanced by a responsable doctor. 

About the author

Ana Luiza Almeida Menezes and Emilly Mota Linhares are second year medical students in the Tiradentes University. They are members of International Federation of Medical Students Association in Brazil (IFMSA – Brazil) and strongly believe in the power of scientific research and the possibility of new pathways for COVID-19 treatment.

the sting Milestones

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

Coronavirus: European roadmap shows path towards common lifting of containment measures

MasterCard @ MWC14: Innovation in times of regulatory uncertainty

Ending the era of dirty textiles

Big data is coming to agriculture. Farmers must set its course

A reality check on inclusive innovation

Trump’s Russophiles under investigation, Europe remains ‘en garde’

How a trade war would impact global growth

This Japanese experiment shows how easily coronavirus can spread – and what you can do about it

UNESCO lists wrestling, reggae and raiho-shin rituals as global treasures to be preserved

Eurozone’s sovereign debt not a problem anymore?

Does the EU want GMOs and meat with hormones from the US?

Why your next work meeting should be a ‘walk-and-talk’

Meet Alice, the battery-powered plane that could herald the age of electric air travel

WEF Davos 2016 LIVE: “You just don’t know if the oil price will be 20$ or 100$ in the next 2-3 years!” top Harvard economist Kenneth Rogoff underscores from Davos

Mobile health technology: Advances, Facilitations and Promotion of Autonomy

A Sting Exclusive: “Cybersecurity Act for safer European Industries and Consumers against cyberthreats”, by MEP Niebler

Why collective action is the key to saving our forests

Commission’s Youth Initiative fails first hurdle by not sufficiently consulting young people

With potential to boost profits by up to 20 per cent, a woman’s place is at work, says UN labour agency

Environmental liability rules need revamping

Lack of involvement, or lack of opportunities?

A roadmap for destination management in the digital economy

ECB: Euro area should smooth out the consumption and income shocks of its members

Coronavirus Global Response: the Commission’s contribution to the COVID-19 Vaccine Global Access Facility (COVAX)

Why protesters disrupted London Fashion Week

‘Think beyond farm jobs’ to reach sustainable development, UN agriculture chief advises African youth

Top officials say UN will support Bahamas’ rescue, relief efforts as Hurricane Dorian churns in Atlantic

From underestimation to valorization: how mobile technology is transforming global health

All sides in Yemen conflict could be guilty of war crimes, UN experts find

MWC 2016 LIVE: Verizon boasts momentum for IoT platform

“At the Environment Assembly citizens expect clean, not hot air”, the Head of UN Environment in Europe underscores in a Sting Exclusive

Mobile Technology Saving Lives: Changing healthcare systems with simple technological solutions

Stop the waste: UN food agencies call for action to reduce global hunger

Don’t dismiss start-ups founded by millennials. This is how they succeed

Myanmar: Departing UN rights expert still hopeful for democratic transition

Will the end of QE come along with ECB’s inflation target?

Permafrost is thawing so fast it’s gouging holes in the Arctic

Brexit mission impossible: Theresa May was so desperate that had to appoint Boris Johnson as Foreign Secretary

European Super League: Why more football is an imperfect solution to sport’s business model problem

Texting is a daily source of stress for 1/3 of people – are you one of them?

ACP-EU Parliamentary Assembly: strengthening the partnership

Everybody against Japan over yen’s devaluation

Nicaragua: MEPs demand an end to repression of political opponents

COVID-19 vaccine development is more global than you might think

What little Cameron got in Brussels seems enough to keep Britain in the EU

It ain’t over until Google says it’s over

Azeri natural gas will keep the EU warm soon

From Policy to Reality: Discrepancies in Universal Health Care Systems across the EU

Is there a de facto impossibility for the Brexit to kick-start?

Militias force nearly 2,000 to leave Libyan capital’s largest shelter for internally-displaced: UNHCR

Visa liberalisation: Commission reports on fulfilment of visa-free requirements by Western Balkans and Eastern Partnership countries

UN chief calls for ‘enlightened self-interest’ from world leaders to save ‘the whole planet’ from climate change

A Europe that Protects: Commission calls for more efforts to ensure adoption of security proposals

World is ‘on notice’ as major UN report shows one million species face extinction

New York City has a plan to fight fast fashion waste. Here’s how it works

Changing world of work needs new jobs strategy

How LA plans to be 1.6°C cooler by 2050

VP McGuinness on women’s rights: “Not an option, but a duty”

Security Union: Commission welcomes political agreement on removing terrorist content online

Discussions kick off among MEPs and national MPs on economic governance

More Stings?


  1. Johan Praamsma says:

    Dear Almeida and Emilly. Your article has several flaws. Next to not referencing your articles, which makes it impossible to check where you found your information, you do not give answer to the title. Which lesson do we have learned? I highly suggest Europeansting to put this article offline as the quality is very low. And I would suggest you look at all the studies (all listed on ivmmeta.com) that have been performed so far on ivermectin combined, before making a conclusion.

  2. Gary Kaplan says:

    The “recent” in vitro research is over a year old and done with monkey kidney cells. an in vitro study cannot tell what would happen in vivo.

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s